Quanterix Reports 12% Revenue Growth in 2024 Despite Market Challenges

Quanterix Reports Strong Revenue Growth Amid Market Challenges

Quanterix Corporation, a leader in advanced biomarker detection technology, announces its preliminary financial results for the fourth quarter and full year ending December 31, 2024. The company, headquartered in Billerica, Massachusetts, showcases its seventh consecutive quarter of double-digit revenue growth, highlighting its resilience in a challenging market landscape. For Q4 2024, Quanterix records approximately $34.9 million in revenue, marking an 11% increase from the same quarter in the previous year. This growth is bolstered by a significant rise in accelerator revenue, which surges by 22% to about $8.6 million, along with a remarkable 57% jump in other revenue, amounting to approximately $5.8 million.

Despite the positive trends in specific revenue streams, Quanterix faces challenges as instruments revenue declines by 6% to around $3.1 million, and consumables revenue remains stagnant at approximately $17.4 million. For the full year 2024, the company reports total revenue of approximately $137.2 million, reflecting a 12% year-over-year increase. Notably, consumables revenue grows by 8% to $69.3 million, while accelerator revenue stands out with a substantial 36% increase, reaching $38 million. This diverse revenue performance illustrates the company's effective navigation through market fluctuations while maintaining a strong portfolio of products.

Looking ahead, President and CEO Masoud Toloue expresses optimism about Quanterix’s operational resilience and growth trajectory as it enters 2025. The recent acquisition of Akoya Biosciences is expected to enhance the company's capabilities and expand its market reach. Quanterix concludes 2024 with a solid cash position of approximately $292 million, despite utilizing about $32 million in cash during the year. The unaudited financial results are subject to final procedures and audits, but the company remains committed to driving scientific discovery through its innovative biomarker detection technologies.

In addition to its financial achievements, Quanterix emphasizes its dedication to advancing research in various fields, including neurology and oncology. The company’s technologies play a crucial role in enabling researchers to gain deeper insights into disease mechanisms and therapeutic outcomes. As the demand for precision medicine and biomarker analysis continues to grow, Quanterix is well-positioned to lead in this evolving market.

With a focus on innovation and strategic growth, Quanterix Corporation continues to strengthen its position as a key player in the biomarker detection industry, paving the way for future advancements in healthcare and scientific discovery.